InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,431.60
(
-0.04%
)
US TECH 100
19,168.00
(
0.52%
)
Dow Jones
38,589.16
(
-0.15%
)
Brent Oil
82.28
(
0.00%
)
Bitcoin
66,282.00
(
0.42%
)
Post# of 252188
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Replies (2) Keep Next 10 Report Keyboard Shortcuts
Replies (2) Next 10 Prev Next

Biowatch

Send PM Follow Ignore
Followers 59
Posts 6624
Boards Moderated 1
Alias Born 10/18/2003

Biowatch

Member Level

Re: DewDiligence post# 196096

Friday, 10/23/2015 10:46:21 AM

Friday, October 23, 2015 10:46:21 AM

Post# of 252188
If the patient's "original"/"native" cells outgrow GT treated cells, it will wash out the benefits of gene therapy.

A second round of GT may be necessary to continue the benefit.

It is still better than a lifetime of transfusions, which lead to a toxic build-up of iron in the blood.
Public Reply Private Reply New Post
Keep Last Read
Replies (2) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (2) Next 10 Prev Next

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up